Elsevier Announces 2010 Journal Impact Factor Highlights
Amsterdam, 14 July, 2011 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the highlights of its journal Impact Factor performance in 2010. According to the 2010 Journal Citation Reports® published by Thomson Reuters, Elsevier saw over 55% of its journal Impact Factors increase from 2009 to 2010, while slightly over 49% of non-Elsevier journals showed an increased Impact Factor. In addition, 23% of Elsevier journals were ranked in the top 10% of their category.
Glen Campbell, Executive Vice President, Global Medical Research Journals said, “It continues to give us pride to be able to announce increased Impact Factors year after year. It’s a tribute to the authors, reviewers and editors we work with, as it’s their dedication, professionalism and integrity that enable us to publish world class-content. We are mindful however, that the Impact Factor is just one of a number of quality indicators for journals.”
Martin Tanke, Managing Director of Elsevier’s Science & Technology Journals, added, “We continue to look at ways to improve the quality of our journals beyond the Impact Factor. Speeding up the reviewing process, investing in tools that further streamline the publishing process and continuous efforts to enhance peer review are some of our top priorities in this area. Let there be no doubt, however, that we are delighted to see this year’s significant Impact Factor increases.”
The Lancet and all three Lancet specialty journals improved their Impact Factors this year. The Lancet went up from 30.758 to 33.633, ranking 2nd in the Medicine, General & Internal category. Lancet Infectious Diseases and Lancet Neurology retained their #1 rankings in their respective categories, while Lancet Oncology saw its Impact Factor increase from 14.470 to 17.764.
Cell, the flagship journal of Cell Press, saw its Impact Factor increase from 31.152 to 32.401 and remains the number one research journal in the Cell Biology and Biochemistry & Molecular Biology subject categories. The impact factor for Immunity showed an impressive 18% increase to 24.221. Among Cell Press’s more recent suite of journal launches, Cancer Cell delivered a strong performance by showing an increase of almost 7% to 26.925, while Cell Stem Cell (increase to 25.943)and Cell Host & Microbe(increase to 13.728)continue to grow in their third year of impact factors.
In addition, 67 Elsevier journals earned their first Impact Factor this year. Some of these journals received very impressive scores including:
Communications in Non-Linear Science and Numerical Simulation (2.697) - entering in the top ten of three categories:
- 6th in the Mathematics, Applied category of 236 journals,
- 5th in the Mathematics, Interdisciplinary Applications category of 92 journals,
- 5th in the Physics, Fluids & Plasmas category of 31 journals.
- History of the Family (0.595) – entering the Orthopedics category ranked 8th of 26 journals.
- JACC-Cardiovascular Imaging (5.528) - entering the Radiology, Nuclear Medicine & Medical Imaging category ranked 4th of 111 journals and ranked 11th in the Cardiac & Cardiovascular Systems category of 114 journals.
- JACC-Cardiovascular Interventions (5.862) - entering the Cardiac & Cardiovascular Systems category of 114 journals in 10thplace.
The Impact Factor is a measure of the frequency with which the average article in a journal has been cited in a particular year. The Impact Factor helps to evaluate a journal’s relative importance, especially when compared with others in the same field.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Vice President, Global Corporate Relations
+1 215 239 3508